NYLIM
BPMC

New York Life Investment Management’s Blueprint Medicines BPMC Stock Holding History

New York Life Investment Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,173
Closed -$664K – 826
2024
Q3 		$664K Buy
+7,173
New +$713K 0.01% 784

Other funds holding BPMC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

New York Life Investment Management's BPMC Position: Q4 2024 in Review

New York Life Investment Management sold out of Blueprint Medicines (BPMC) in Q4 2024, closing a stake of 7,173 shares — an estimated $664K sold.

New York Life Investment Management first reported a position in BPMC in Q3 2024 and held it in 1 quarter. The position peaked at $664K in Q3 2024. 345 funds tracked by Wall St. Rank hold BPMC as of Q4 2024.

  • New York Life Investment Management reported no remaining Blueprint Medicines position as of Q4 2024 after selling out during the quarter.
  • New York Life Investment Management sold 7,173 Blueprint Medicines shares in Q4 2024, an estimated $664K.
  • New York Life Investment Management first reported a position in Blueprint Medicines in Q3 2024 and held it in 1 quarter.
  • New York Life Investment Management's Blueprint Medicines position peaked at $664K in Q3 2024.
  • 345 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2024.

Based on New York Life Investment Management's 13F filing for Q4 2024, filed 5 Feb 2025.